Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0063—Periodont
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics

Definitions

• the present invention relates to pharmaceutical compositions allowing the sustained release of at least one active substance, to processes for the preparation of these compositions, as well as to their use for the administration of medicaments by the subcutaneous route and / or intramuscular.
• TRH thyrotropin releasing hormone a tripeptide
• Another means of prolonging the release of an active principle consists in its incorporation in an implant.
• These implants can be prepared from biodegradable polymers or not.
• the drawback of this form is linked to its mode of subcutaneous introduction by incision or using a trocar.
• the implant must be removed by incision after diffusion of all of the active ingredient out of the polymer matrix.
• hormones such as LHRH (luteinizing hormone releasing hormone) and its synthetic analogues.
• goserelin administered to humans in the form of implants of PLA-GA allows a very significant and lasting decrease in the level of testosterone in the blood (Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA, Caplan RJ and Kennealey GT, Urolog, 46, 220 (1995)).
• micro or nanoparticles can also be used: micro or nanoparticles.
• biodegradable polymers are used. Compared to implants, these particles can be injected using a conventional syringe but have the disadvantage that they cannot be removed from the body. In case of problem. A very significant and lasting decrease in testosterone levels has also been observed in humans after administration of microparticles of PLA-GA containing nafarelin.
• compositions obtained by an extremely simple preparation process and which allow a prolonged release of an active principle. These compositions have the property of instantly gelling in the presence of an aqueous phase. They can therefore be judiciously used to obtain, by the subcutaneous and intramuscular routes, a sustained and programmed release of drugs. On contact with the mucous membranes, a gel will form under the skin or in the muscle and the medicine may diffuse and be released from the gel. Lipid compositions which undergo a phase transformation on contact with water have already been presented in the literature.
• European patent application 550960 describes compositions for topical application, intended to prevent sweating, comprising a sweating-preventing agent, which comprises at least one amphiphilic substance, this sweating-preventing agent being capable of forming a liquid crystalline phase insoluble in with a periodicity greater than 1.
• Example 14 illustrates a composition capable of forming a reverse hexagonal crystalline phase in contact with perspiration, composed of 34 to 50% of oleic acid and of 50 to 66% lecithin (phosphatidylcholine).
• International patent application WO 94/10978 describes emulsifying compositions intended to replace the synthetic emulsifiers commonly used in the food, cosmetic, grooming or pharmaceutical industry.
• compositions comprise at least one membrane lipid (phospholipid), at least one natural amphiphile which is not a primary emulsifier (fatty acid or fatty alcohol C12 to C22, or combination of a fatty acid and a fatty alcohol), and, optionally, a hydrophilic medium (aliphatic alcohol such as propylene glycol).
• phospholipid phospholipid
• natural amphiphile fatty acid or fatty alcohol C12 to C22, or combination of a fatty acid and a fatty alcohol
• hydrophilic medium aliphatic alcohol such as propylene glycol
• Example 4 describes a composition consisting of 15% by weight of hydrogenated soy lecithin (phospholipid), 15% by weight of fatty acid, 45% by weight of fatty alcohol and 25% by weight of alcohol (10% ethanol and 15% glycerol).
• This composition is in the form of a wax (soft waxy mass).
• the literature also mentions fluid pharmaceutical compositions intended for the treatment of paradontitis, being in the form of more or less viscous suspensions or emulsions which are administered in the periodontal pocket, generally using syringes.
• biodegradable lipid compositions in the form of L2 crystalline phases, allowing the controlled release of active substances and comprising, in addition to the active substance, at least one diacyl glycerol of unsaturated fatty acid having 16 with 22 carbon atoms or saturated fatty acid atoms having from 14 to 22 carbon atoms, and at least one phospholipid chosen from glycerophosphatides and sphingophosphatides, and, optionally, at least one polar liquid chosen from water, glycerol, ethylene glycol and propylene glycol.
• compositions have the particularity of transforming in contact with water into cubic liquid crystalline phases, which makes it possible to "mold" the active substance in the site where it is desired that the action takes place.
• This document mentions, among other applications, the possibility of using such compositions for the treatment of periodontitis.
• the effectiveness of such compositions in the treatment of periodontitis is not illustrated in this document.
• European patent 429224 describes compositions in the form of gels containing from 1 to 99% by weight of monoolein and from 1 to 90% by weight of active substance, which are placed in the periodontal cavity. In the presence of surrounding water, these compositions become more viscous and keep the active substance close to its site of action. The active substance is released slowly in a controlled manner.
• US Patent 5,230,895 describes the use of compositions in the form of solutions or pastes capable of transforming into a gel when they have been placed in the periodontal pocket. These compositions are biodegradable and allow the controlled release of the active substance, in the site of action.
• compositions illustrated in this document contain at least 70% of Myverol TM 18-92 which is a composition of sunflower monoglycerides having a monoglyceride content of at least 90%.
• compositions allowing the administration by controlled release of an active substance in a periodontal pocket, comprising at least one monoglyceride and at least one vegetable oil in proportions sufficient to form a liquid crystalline phase in contact with the water present in the periodontal pocket.
• These compositions are solid at room temperature, but have a melting point below body temperature.
• the present invention relates to fluid pharmaceutical compositions allowing the controlled release of at least one active substance comprising a) a therapeutically effective amount of at least one active substance, b) from 3 to 55% by weight of phospholipid, c) from 16 at 72% by weight of pharmaceutically acceptable solvent, and d) from 4 to 52% by weight of fatty acid, these compositions having the property of instantly gelling in the presence of an aqueous phase.
• the invention relates to processes for the preparation of these compositions.
• antibiotics in particular antibiotics active against anaerobic bacteria such as doxycycline or minocycline and their pharmaceutically acceptable salts, anti-infectious agents, such as metronidazole, chlorhexidine, benzalkonium chloride , p-chloro-m-cresol, 1,2-dichlorobenzyl alcohol, hexamidine or chlorofen and their pharmaceutically acceptable salts, local anesthetics such as lidocaine, procaine, tetracaine, articaine, bupivacaine, mepivacaine or prilocaine and their pharmaceutically acceptable salts, steroidal anti-inflammatory drugs or others, such as hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone or dexamethasone and pharmaceutically acceptable as well as aceclofenac, diclofenac, ibuprof
• compositions according to the present invention contain from 3 to 55% of phospholipid.
• the phospholipids which can be used according to the present invention are phosphoric esters of polyols and of fatty acids. They can come from a wide variety of sources, both natural and synthetically.
• the phospholipids can be hydrogenated or non-hydrogenated. Examples that may be mentioned are phosphatidylcholine, hydrogenated phosphatidylcholine, phosphatidylglycerol salts, dicaproylphosphatidylcholine or salts of distearoylphosphatidylglycerol. These phospholipids can also be used as a mixture.
• the phospholipid present in the compositions according to the present invention is phosphatidylcholine.
• compositions according to the present invention can also contain up to 15% by weight of water.
• amount of water present in the compositions according to the invention is chosen so that the composition has the desired consistency for the intended application.
• phospholipids in the form of commercial mixtures are suitable for the compositions according to the present invention.
• Phosal 50 PG TM 55.8% phosphatidylcholine, 1.9% soy fatty acids, 2.9% sunflower monoglycerides, 1.9% ethanol, 37 , 3% propylene glycol, 0.2% ascorbyl palmitate
• Phosal 53 MCT TM 60.8% phosphatidylcholine, 2% oleic acid, 3% sunflower monoglycerides, 5% ethanol, 29% triglycerides, 0.2% ascorbyl palmitate
• NATTERMANN PHOSPHOLIPID GmbH available from NATTERMANN PHOSPHOLIPID GmbH.
• compositions according to the present invention can also contain the following optional components: up to 5% by weight of monoglyceride or diglyceride or of a mixture of mono- and diglyceride and / or up to 15% by weight of triglycerides.
• compositions according to the present invention may also contain one or more preserving agents (such as ethanol), one or more antioxidant agents (such as ascorbyl palmitate) or one or more complexing agents (such as EDTA ( ethylenediamine tetraacetate)).
• preserving agents such as ethanol
• antioxidant agents such as ascorbyl palmitate
• complexing agents such as EDTA ( ethylenediamine tetraacetate)
• compositions according to the present invention allow the controlled release of at least one active substance.
• controlled release is meant a release profile of the active substance desirable for the treatment envisaged.
• the release of the active substance can therefore be more or less retained or slowed down depending on the active substance used and the desired therapeutic effect.
• control of the release of the active substance can be easily obtained by simple variations in the proportions of the components of the compositions according to the present invention. They therefore lend themselves very well to various therapeutic applications in which the controlled release of an active substance is sought in a very specific biological site.
• compositions according to the present invention are fluid pharmaceutical compositions in the form of emulsions, suspensions or oily preparations. They have the property of instantly gelling in the presence of an aqueous phase. In fact, when the compositions according to the present invention are placed in the presence of an excess of aqueous phase, they pass from a fluid state to a state of gel immiscible with the surrounding aqueous phase.
• the present invention relates to methods of preparing the compositions according to the present invention.
• the compositions according to the present invention are obtained by a process comprising the following successive stages: i) the phospholipid (s) are dissolved in the pharmaceutically acceptable solvent (s); ii) the fatty acid (s) are added to the phospholipid solution with stirring; iii) the active substance or substances are incorporated into the mixture obtained at the end of stage ii), and iv) water is optionally added to the composition obtained in stage iii).
• the active substance is water-soluble, it is dissolved in a minimum quantity of water before incorporation in step iii).
• step iii) When the substance active is not soluble in water, it is incorporated in step iii) in the mixture of phospholipid, pharmaceutically acceptable solvent and fatty acid. In the case of a substance which is both water-insoluble and little or no liposoluble, it is also incorporated in step iii), optionally in micronized form.
• step iiii When the substance active is not soluble in water, it is incorporated in step iii) in the mixture of phospholipid, pharmaceutically acceptable solvent and fatty acid. In the case of a substance which is both water-insoluble and little or no liposoluble, it is also incorporated in step iii), optionally in micronized form.
• the examples which follow illustrate the present invention without however limiting it. In these examples, all parts are expressed by weight.
• the following commercial products were obtained from NATTERMANN PHOSPHOLIPID GmbH and have the following compositions (percentages by weight): - Phospholipon 90 TM: phosphatid
• - Phosal 50 PG TM 55.8% phosphatidylcholine, 1.9% soy fatty acids, 2.9% sunflower monoglycerides, 1.9% ethanol, 37.3% propylene glycol, 0 , 2% ascorbyl palimitate;
• - Phospholipon G-Na TM sodium salt of soybean 3 (3-sn-phosphatidyl) glycerol
• - Phospholipon CC TM 1,2-dicaproyl-sn-glycero (3) phosphocholine
• Phospholipon SG-Na TM sodium salt of 1,2-distearoyl-sn-glycero (3) phospholglycerol;
• Example 2 The preparations Zj to Z5 prepared in Example 1 were subjected to a release test carried out according to the standards of the 23 rd edition of the US pharmacopoeia (USP 23), using apparatus No. 1 at a temperature of 37 ° C., the blades rotating at 50 rpm.
• composition O Phospholipon 90 (30 parts by weight) is dissolved hot in polyethylene glycol 400 (45 parts by weight). After cooling, the oleic acid is added with stirring. On contact with an aqueous solution, the preparation instantly gels.
• compositions P 40.9 parts of NAT 8449 TM are mixed with stirring,
• compositions according to the present invention can contain different types of phospholipids.
• the phospholipids used are the sodium salt of soybean 3- (3-sn-phosphatidyl) glycerol (Phospholipon G-Na TM), 1,2-dicaproyl-sn-glycero (3) phosphocholine (Phospholipon CC TM), the salt sodium 1,2-distearoyl-sn-glycero (3) phosphoglycerol (Phospholipon SG-Na TM) and hydrogenated soybean (3-sn-phosphatidyl) choline (Phospholipon 90H TM)
• compositions S presented in Table 11 are obtained by mixing the various components with stirring. These four compositions instantly gel in the presence of an aqueous phase.
• Example 7 Measurement of the release rate as a function of the excipients.
• the release test is carried out as follows. Equal quantities of the preparations T j to T ⁇ and the control solution are placed in a well dug in the center of a layer of constant thickness of trypticase soy agar poured into a Petri dish. The rate of diffusion of the dye is determined by measuring the diameter of the dye stain as a function of time. The results obtained for the control solution and the Ti to T ⁇ solutions are included in the
• compositions U listed in Table 14 were prepared.
• Example 7.1 A release test as described in Example 7.1 is carried out on the compositions U1 to U4; for comparison, a release test is simultaneously carried out with the T7 solution and with a 10% solution of Sicomet-FDC blue 1 (control). The results of this test are presented in Table 15.
• Example 8 In vivo tests. Subcutaneous and intramuscular injection of a calcitonin preparation. Calcitonin causes a decrease in the serum calcium level in direct relation to its activity. During these tests, the evolution over time of the serum calcium level in the rat was monitored after subcutaneous or intramuscular injection of preparations according to the invention containing 20 ⁇ l of salmon calcitonin.
• compositions comprising salmon calcitonin used in these tests are listed in Table 16.
• each rat receives subcutaneously in the abdominal region 200 ⁇ l of the preparation X ⁇ , ie 20 ⁇ l of calcitonin;
• each rat receives subcutaneously in the abdominal region 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin;
• each rat receives intramuscularly into the thigh muscle 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin; • series 6: each rat receives intramuscularly into the thigh muscle 200 ⁇ l of preparation X2, ie 20 ⁇ l of calcitonin.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Dispersion Chemistry (AREA)
• Dermatology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Anesthesiology (AREA)
• Communicable Diseases (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=3891230

Family Applications (2)

Family Applications After (1)

Country Status (25)

Cited By (40)

Families Citing this family (120)

Citations (5)

Family Cites Families (6)

• 1998
  • 1998-04-30 BE BE9800329A patent/BE1011899A6/fr active
• 1999
  • 1999-04-16 RS YUP-666/00A patent/RS50025B/sr unknown
  • 1999-04-16 ID IDW20002199A patent/ID26221A/id unknown
  • 1999-04-16 JP JP2000546753A patent/JP2002513749A/ja not_active Withdrawn
  • 1999-04-16 EA EA200001125A patent/EA002530B1/ru not_active IP Right Cessation
  • 1999-04-16 TR TR2000/03158T patent/TR200003158T2/xx unknown
  • 1999-04-16 US US09/674,159 patent/US6464987B1/en not_active Expired - Fee Related
  • 1999-04-16 KR KR1020007011844A patent/KR100567975B1/ko not_active Expired - Fee Related
  • 1999-04-16 HU HU0101580A patent/HU226556B1/hu not_active IP Right Cessation
  • 1999-04-16 CA CA002330500A patent/CA2330500C/fr not_active Expired - Fee Related
  • 1999-04-16 DE DE69901951T patent/DE69901951T2/de not_active Expired - Fee Related
  • 1999-04-16 WO PCT/EP1999/002551 patent/WO1999056725A1/fr not_active Ceased
  • 1999-04-16 AU AU37085/99A patent/AU3708599A/en not_active Abandoned
  • 1999-04-16 EP EP99923418A patent/EP1073415B1/fr not_active Expired - Lifetime
  • 1999-04-16 DK DK99923418T patent/DK1073415T3/da active
  • 1999-04-16 IL IL13911399A patent/IL139113A0/xx not_active IP Right Cessation
  • 1999-04-16 WO PCT/EP1999/002552 patent/WO1999056726A1/fr not_active Ceased
  • 1999-04-16 AT AT99919243T patent/ATE219659T1/de not_active IP Right Cessation
  • 1999-04-16 EP EP99919243A patent/EP1073414B1/fr not_active Expired - Lifetime
  • 1999-04-16 ES ES99923418T patent/ES2249891T3/es not_active Expired - Lifetime
  • 1999-04-16 AT AT99923418T patent/ATE307569T1/de not_active IP Right Cessation
  • 1999-04-16 NZ NZ507707A patent/NZ507707A/en unknown
  • 1999-04-16 JP JP2000546752A patent/JP2002513748A/ja active Pending
  • 1999-04-16 CN CNB998062669A patent/CN1183901C/zh not_active Expired - Fee Related
  • 1999-04-16 DE DE69927963T patent/DE69927963T2/de not_active Expired - Fee Related
  • 1999-04-16 ES ES99919243T patent/ES2178430T3/es not_active Expired - Lifetime
  • 1999-04-16 AU AU40308/99A patent/AU738455B2/en not_active Ceased
  • 1999-04-16 BR BR9910066-5A patent/BR9910066A/pt not_active Application Discontinuation
• 2000
  • 2000-04-16 US US09/674,163 patent/US6471970B1/en not_active Expired - Fee Related
  • 2000-10-17 BG BG104872A patent/BG64723B1/bg unknown
  • 2000-10-17 IS IS5669A patent/IS2354B/is unknown
  • 2000-10-23 ZA ZA200005915A patent/ZA200005915B/xx unknown
  • 2000-10-27 NO NO20005431A patent/NO20005431L/no not_active Application Discontinuation
• 2002
  • 2002-09-17 US US10/259,366 patent/US6818224B2/en not_active Expired - Fee Related

Patent Citations (5)

Also Published As

Similar Documents

Legal Events